Mitch McConnell congratulates Joe Biden, Kamala Harris for election win
16-12-2020, 10:04

Font size: [ A+ ] / [ A- ]

WASHINGTON – Senate Majority Leader Mitch McConnell, R-Ky., recognized former Vice President Joe Biden as the president-elect for the first time Tuesday, one day after the Democratic ticket sealed an Electoral College victory. 

“The Electoral College has spoken,” McConnell said during a speech on the Senate floor in which he also praised President Donald Trump's accomplishments. McConnell said he wanted to “congratulate President-elect Joe Biden” and Vice President-elect Kamala Harris.

"The President-elect is no stranger to the Senate. He has devoted himself to public service for many years," McConnell said of Biden. 

Noting Harris’ historic win as the first female vice president, McConnell said, “beyond our differences, all Americans can take pride that our nation has a female vice president for the very first time.”

For weeks, McConnell had declined to acknowledge Biden's victory and had said Trump had the right to litigate the results, though McConnell had promised an "orderly transfer" between administrations. Courts have rejected most of the Trump campaign's court challenges seeking to overturn Biden's win.

Trump has not formally conceded the election. Biden in a Monday night speech reaffirmed his victory and denounced Trump's baseless claims of fraud, saying it was "time to turn the page as we’ve done throughout our history."

Speaking after McConnell, Senate Minority Leader Chuck Schumer, D-N.Y., said other Republicans "ought to follow McConnell's lead" and recognize Biden's win. 

Biden said Tuesday he spoke with McConnell and thanked him for his floor remarks.

The president-elect, who is traveling to Georgia to campaign for Democratic Senate candidates, said he had a “good conversation with Mitch McConnell today.”

Biden, who told reporters he was calling "about a dozen" other lawmakers, said he told McConnell that, though they disagreed on many issues, he hoped they could find common ground.

"We agreed to get together sooner than later. And I'm looking forward to working with him," he said. 

Republican lawmakers slowly started to accept Biden as president-elect after Monday’s Electoral College vote again certifying Biden's victory, though some lawmakers said they wanted to wait for the end of litigation and for Congress to certify the Electoral College results on Jan. 6. A group of House Republicans led by Rep. Mo Brooks, R-Ala., has said they plan to challenge the results in an effort unlikely to change the outcome. 

Senate Republicans likely will not join in their effort.

Sen. Shelley Moore Capito, R-W.V., told reporters on Capitol Hill Senate Republican leadership had encouraged members during a Tuesday conference call "to accept the result as much as it's not what we...would have envisioned for the next four years and to try to do what's best for the American people. " 

She said there was not any pushback from other senators on the call. 

 Sen. John Barrasso, R-Wyo., a member of Senate Republican leadership, told reporters Tuesday he did not know of any Republican senators willing to join the House lawmakers' effort. 

The second-ranking Senate Republican, John Thune of South Dakota, said Monday "once the Electoral College settles the issue today, it's time for everybody to move on."

And the Republican senator in charge of the committee planning the inauguration, Roy Blunt of Missouri, told reporters Biden was the president-elect and that his committee would work with the incoming president.  

Some Republican senators addressed Biden's win with a caveat. Sen. Thom Tillis, R-N.C., said Biden was now the "presumptive president" following the Electoral College votes, but he said remaining legal disputes needed to be resolved.

 

MSN

 

Comments: 181
#1   Rodolfo
      
CJC‑1295 and ipamorelin side effects safety are two peptide hormones that work together to enhance the body’s natural growth hormone production.
CJC‑1295 is a long‑acting analogue of growth hormone releasing hormone, while
Ipamorelin is a selective growth hormone secretagogue that stimulates the pituitary gland to release
growth hormone without significantly affecting cortisol
or prolactin levels. When combined, these peptides produce a
more robust and sustained increase in circulating growth
hormone than either agent alone.



Jump to



Side effects associated with CJC‑1295 and Ipamorelin are usually mild and temporary, but they can vary from person to person. The most commonly reported symptoms include injection site reactions such as redness, swelling or pain at the needle puncture area.
Some users experience headaches, dizziness or a feeling of lightness in the head after
the first few doses. A slight increase in appetite is also frequent, especially when growth hormone levels rise rapidly.




Other possible side effects involve fluid retention and mild edema, which can lead to temporary puffiness around the face,
hands or feet. In rare cases, users may notice joint pain or stiffness that resolves once the peptide regimen is stopped.
Because both peptides influence insulin sensitivity, people with diabetes or those
prone to blood sugar fluctuations should monitor
their glucose levels closely.



It is worth noting that CJC‑1295 and Ipamorelin can affect the hypothalamic‑pituitary‑adrenal axis in a
subtle way. Although they do not typically raise cortisol levels as much as other growth hormone secretagogues, some users report increased anxiety or mood swings during the initial phase of treatment.
These emotional changes are usually short‑lived and
diminish after the body adapts to the new hormonal balance.




For most healthy adults, long‑term use of CJC‑1295 and Ipamorelin appears safe when dosed correctly under
medical supervision. Nevertheless, some potential risks remain,
especially with prolonged high doses. Chronic elevation of growth hormone may contribute to an increased risk of developing insulin resistance or type 2
diabetes over time. Additionally, the continuous stimulation of growth plates
could theoretically affect bone density or joint health in certain populations.




In summary, while CJC‑1295 and Ipamorelin are generally well tolerated, users should
remain vigilant for injection site irritation, fluid retention, headaches, increased appetite,
mood changes and blood sugar fluctuations. Regular monitoring of vital signs, hormone levels
and metabolic parameters can help identify any adverse effects
early, allowing adjustments to dosage or treatment schedule before serious complications arise.
6 October 2025 01:07
Add Comments

Name:*
E-Mail:
  Geo Keyboard  
 

Dear reader, guardian.ge welcomes your comments. Please express your views on topic and be respectful of others.

bold italic underline strike | align left centered align right | Ensert smilies insert linkInsert protected URL Choice the color | hidden text insert quote Convert selected text from transliteration to Cyrillic alphabet Insert spoiler

Code: *


Back1 2 3 4 5 6 7 8 9 10 Next